146 related articles for article (PubMed ID: 32799779)
1. Acute pancreatitis in a patient treated with imatinib and gefitinib.
Escudero-Vilaplana V; Collado-Borrell R; Villanueva-Bueno C; Álvarez R; Herranz A; Sanjurjo M
J Oncol Pharm Pract; 2021 Jun; 27(4):980-983. PubMed ID: 32799779
[TBL] [Abstract][Full Text] [Related]
2. The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients.
Nesr G; Claudiani S; Khorashad J; Apperley J; Milojkovic D
Leuk Lymphoma; 2019 Dec; 60(13):3333-3334. PubMed ID: 31232126
[No Abstract] [Full Text] [Related]
3. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
Harding DJ; MacQuillan G; Howman R; de Boer B; Adams L; Mitchell A; Jeffrey G
J Clin Oncol; 2016 Apr; 34(11):e97-8. PubMed ID: 25267743
[No Abstract] [Full Text] [Related]
4. Imatinib mesylate-induced acute hepatotoxicity.
Frikha I; Fakhfakh Y; Sahnoun R; Chtourou L; Medhaffar M; Elloumi M
J Oncol Pharm Pract; 2023 Dec; 29(8):2027-2030. PubMed ID: 37464887
[TBL] [Abstract][Full Text] [Related]
5. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
6. Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.
Osorio S; Escudero-Vilaplana V; Gómez-Centurión I; González-Arias E; García-González X; Díez JL
J Oncol Pharm Pract; 2019 Apr; 25(3):694-698. PubMed ID: 29199506
[TBL] [Abstract][Full Text] [Related]
7. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
[No Abstract] [Full Text] [Related]
8. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
Etienne G; Guilhot J; Rea D; Rigal-Huguet F; Nicolini F; Charbonnier A; Guerci-Bresler A; Legros L; Varet B; Gardembas M; Dubruille V; Tulliez M; Noel MP; Ianotto JC; Villemagne B; Carré M; Guilhot F; Rousselot P; Mahon FX
J Clin Oncol; 2017 Jan; 35(3):298-305. PubMed ID: 28095277
[TBL] [Abstract][Full Text] [Related]
9. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
[No Abstract] [Full Text] [Related]
10. Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
Ángeles-Velázquez JL; Hurtado-Monroy R; Vargas-Viveros P; Carrillo-Muñoz S; Candelaria-Hernández M
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S82-5. PubMed ID: 27521331
[TBL] [Abstract][Full Text] [Related]
11. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
12. Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.
Stella S; Tirró E; Massimino M; Vitale SR; Russo S; Pennisi MS; Puma A; Romano C; DI Gregorio S; Innao V; Stagno F; DI Raimondo F; Musolino C; Manzella L
In Vivo; 2019; 33(5):1593-1598. PubMed ID: 31471409
[TBL] [Abstract][Full Text] [Related]
13. The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.
Soysal T; Eskazan AE; Serin I; Sadri S; Keskin D; Ozgur Yurttas N; Berk S; Erdogan Ozunal I; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Ozbek U; Aydin Y
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e377-e384. PubMed ID: 31088736
[TBL] [Abstract][Full Text] [Related]
14. miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
Ramachandran SS; Muiwo P; Ahmad HM; Pandey RM; Singh S; Bakhshi S; Kumar L; Bhattacharya A; Gupta YK
Leuk Lymphoma; 2017 Aug; 58(8):1981-1984. PubMed ID: 28093001
[No Abstract] [Full Text] [Related]
15. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia.
McGrath K; Stein B; Kalhagen L; Leighton L
Ann Allergy Asthma Immunol; 2017 Jul; 119(1):85-86. PubMed ID: 28499700
[No Abstract] [Full Text] [Related]
17. Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients.
Chandrasekhar C; Kumar PS; Sarma PVGK
Sci Rep; 2019 Feb; 9(1):2412. PubMed ID: 30787317
[TBL] [Abstract][Full Text] [Related]
18. Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
Singh S; Sharma PK
Indian J Pharmacol; 2016; 48(4):458-459. PubMed ID: 27756963
[TBL] [Abstract][Full Text] [Related]
19. Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
Shi CR; Nambudiri VE
Am J Hematol; 2018 Mar; 93(3):467-468. PubMed ID: 28836284
[No Abstract] [Full Text] [Related]
20. Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Musolino C; Allegra A; Mannucci C; Russo S; Alonci A; Maisano V; Calapai G; Gangemi S
Turk J Haematol; 2015 Jun; 32(2):168-71. PubMed ID: 26316486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
